Jabbehdari Sayena, Yazdanpanah Ghasem, Cantor Louis B, Hajrasouliha Amir Reza
Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, IL, USA.
Ann Transl Med. 2022 Oct;10(19):1072. doi: 10.21037/atm-22-2730.
Retinal vein occlusion (RVO) is a major cause of vision loss and elevated intraocular pressure (IOP), high ocular perfusion pressure, and glaucoma are known ophthalmic risk factors for RVO. The aim of this paper is to provide the update on the association and management of high IOP/glaucoma and RVO.
A literature review was performed in PubMed and Medline until May 2022 utilizing specific keywords and cross-matched reference lists.
The association of RVO with high IOP/glaucoma may be attributed to retinal ganglion cell loss due to retinal ischemia in high IOP and glaucoma. As new modalities showed, decreased optic disc perfusion, reduced density of blood vessels in the optic nerve head of glaucoma patients, changes in the peripapillary microvascular parameters, and decreased retinal nerve fiber layer (RNFL) thickness of the optic nerve head of eyes with RVO suggest a common pathway between RVO and glaucoma. Literature suggests the close follow up for glaucoma development among patients with non-arteriovenous (AV) crossing (optic cup or optic nerve sited) RVO in fellow eye and management of elevated IOP among RVO cases treated with anti-vascular endothelial growth factor (VEGF) antibodies/corticosteroids and those with preexisting primary open angle glaucoma (POAG).
Determining potential patient responses to treatment and considering therapeutic options are challenging among patients with RVO and glaucoma. However, IOP lowering managements in preventing IOP spikes in patients with preexisting glaucoma and early treatment of macular edema in eyes with RVO is recommended.
视网膜静脉阻塞(RVO)是视力丧失的主要原因,而高眼压、高眼灌注压和青光眼是已知的RVO眼科危险因素。本文旨在提供有关高眼压/青光眼与RVO之间关联及管理的最新信息。
截至2022年5月,在PubMed和Medline上进行了文献综述,使用了特定关键词并交叉匹配了参考文献列表。
RVO与高眼压/青光眼的关联可能归因于高眼压和青光眼中视网膜缺血导致的视网膜神经节细胞丢失。正如新的研究模式所示,青光眼患者视盘灌注减少、视神经乳头血管密度降低、视乳头周围微血管参数改变以及RVO患者视神经乳头视网膜神经纤维层(RNFL)厚度降低,提示RVO与青光眼之间存在共同途径。文献表明,对于对侧眼无动静脉(AV)交叉(视杯或视神经位置)的RVO患者,应密切随访青光眼的发生情况,对于接受抗血管内皮生长因子(VEGF)抗体/皮质类固醇治疗的RVO病例以及患有原发性开角型青光眼(POAG)的患者,应控制眼压升高。
对于RVO和青光眼患者,确定潜在的患者治疗反应并考虑治疗选择具有挑战性。然而,建议降低眼压以预防已有青光眼患者的眼压峰值,并对RVO患者的黄斑水肿进行早期治疗。